Last updated: June 9, 2026
GASTROVIST (gadoversetamide) is a gadolinium-based MRI contrast agent used for contrast-enhanced imaging. It is exposed to (1) patent/market exclusivity through formulation, packaging, and use patents; (2) FDA regulatory status and label-change constraints; and (3) competition from other gadoversetamide/other gadolinium chelates that can pressure pricing and share. A detailed, decision-grade investment assessment depends on the FDA listing for the specific dosage form/strength marketed as GASTROVIST and the related Orange Book patent set, plus active litigation and launch history. Those dataset identifiers are not provided in the prompt, so a complete investment-grade fundamentals report with hard dates, patent counts, expiration windows, and generic/biosimilar timing cannot be produced without risking factual errors.
What patents protect GASTROVIST gadoversetamide contrast agent use and formulations?
Answer: No patent- or Orange-Book-derived listing can be stated from the information provided.
How many patents cover gadoversetamide and what types typically appear for contrast agents?
For contrast agents like gadoversetamide, protection usually clusters around:
- Compound and chelate disclosures (earlier core IP)
- Thermodynamic/kinetic stability and manufacturing purity constraints
- Injectable formulation specifics (buffering, pH range, osmolarity/viscosity targets)
- Packaging and container closure systems (extractables/leachables)
- Method-of-use (imaging protocols, anatomic indications, dosing regimens)
- Pediatric and expanded use (when supported by clinical submissions)
- Process patents (synthetic route, purification steps)
No counts, patent numbers, assignees, or jurisdictions can be listed without the Orange Book or comparable patent-register feed for the exact marketed product.
When does GASTROVIST lose exclusivity and what are the key FDA exclusivity timelines?
Answer: No exclusivity end dates can be stated without FDA product identifiers and Orange Book exclusivity entries.
Patent expiration vs exclusivity vs regulatory takedown
Investment timing usually hinges on three overlapping windows:
- Regulatory exclusivity (new chemical entity, new clinical investigation, etc., if applicable)
- Patent expiration (composition, method, formulation, process)
- Enforcement and settlement outcomes (if any Paragraph IV equivalent challenges exist, or if any disputes occurred between reference and ANDA filers)
No hard calendar schedule can be produced without product-specific FDA regulatory history.
What is the Orange Book status of GASTROVIST gadoversetamide?
Answer: Cannot be determined from the prompt.
What to extract from Orange Book for an investment model
For a decision-grade model, the Orange Book pull is used to build:
- Patent list and each patent’s expiration date
- Dosage form mapping (vial size, strength, route)
- Use codes and submission type
- Exclusivity codes (if any)
- Any listed method-of-use patents that can block generics even after compound expiry
None of these identifiers are present in the prompt.
What formulations are protected by GASTROVIST patents?
Answer: No formulation-specific protection can be listed without the product’s patent-by-formulation mapping.
Injectable MRI contrast agent formulation IP typically targets
- pH targets and buffering system
- chelate stability specifications and acceptance criteria
- preservative systems (if any) and sterility assurance method
- particle/aggregate limits
- concentration ranges and dosing conversion logic
No claim scope or patent families can be assigned to GASTROVIST without the underlying patent record.
What method-of-use patents for imaging indications could block generic entry?
Answer: No method-of-use patents can be identified from the provided inputs.
Typical blocking points
For imaging agents, method-of-use patents can be triggered by:
- specific dosing regimes tied to clinical protocols
- specific indications (CNS, abdominal imaging, vascular, oncology staging)
- timing windows for contrast administration and image acquisition
- combination protocols with other imaging modalities
No claim language or patent identifiers can be cited here without the patent set.
Which companies are challenging GASTROVIST and where do Paragraph IV risks exist?
Answer: Cannot be assessed without ANDA/filing history and litigation records for gadoversetamide equivalent products.
What would feed a Paragraph IV risk screen
- ANDA(s) referencing the listed reference product
- Notice-of-Paragraph IV filings and any label carve-outs
- Litigation docket outcomes, stay durations, and injunction posture
None of these case facts appear in the prompt.
What patent litigation affects GASTROVIST and what settlement terms matter for investors?
Answer: No litigation can be mapped.
Settlement drivers that change the investment profile
- trigger date for generic launch
- permissible label scope
- design-around obligations
- mutual dismissals and covenant-not-to-sue terms
- monetary consideration and supply agreements
No docket or settlement information is provided.
How does GASTROVIST compare with other gadolinium MRI contrast agents on competitive pricing and supply?
Answer: A structured competitor comparison cannot be completed without current market pricing, market share, and the specific licensed product positioning (strength, vial size, distribution channels) for GASTROVIST.
Comparator set usually used in diligence
For gadolinium contrast agents, investors typically benchmark:
- meglumine gadoterate (Dotarem class)
- gadobutrol (Gadavist class)
- gadoteridol (ProHance class)
- gadoterate analogs and alternative chelates with similar indications
- region-specific offerings and manufacturing constraints
No GASTROVIST-specific market data is provided.
What generic entry risks exist for GASTROVIST and what would a launch look like?
Answer: No generic launch scenario can be modeled without Orange Book patent mapping and ANDA pipeline data.
How investors model generic risk for contrast agents
- Identify which patents block ANDA approval vs which only affect exclusivity
- Estimate time to FDA approval by pathway and data requirements
- Evaluate manufacturing and stability hurdles
- Assess label comparability and interchangeability in hospital formularies
No patent and regulatory inputs are available in the prompt.
What are the main manufacturing and IP barriers for producing gadoversetamide injectables?
Answer: Manufacturing/IP barrier assessment cannot be made into concrete, decision-grade conclusions without formulation/process patents and CMC specifics tied to GASTROVIST’s approved product.
Barrier categories investors screen
- chelate stability and impurity profiles
- sterilization and container compatibility
- batch reproducibility under tight specification
- compatibility with clinical dosing devices and dilution workflows
No product-process patent record is available in the prompt.
Key takeaways
A decision-grade investment scenario for GASTROVIST requires product-specific FDA regulatory records and an Orange Book patent/exclusivity map to quantify: (1) patent expiration dates and counts by claim type; (2) exclusivity windows; (3) Paragraph IV and litigation/settlement exposure; and (4) generic launch timing. The prompt provides none of the required identifiers, so a hard-data investment and patent fundamentals analysis cannot be produced without risking incorrect dates, patent counts, and regulatory conclusions.
FAQs
- How do Orange Book patent lists affect generic timing for gadolinium MRI contrast agents like gadoversetamide?
- What claim types most often block ANDA entry for injectable MRI contrast products?
- How do label and dosing protocol differences impact substitutability for MRI contrast agents in hospitals?
- What litigation signals indicate settlement-driven generic launch for contrast agents?
- How do container-closure and formulation stability parameters translate into enforceable IP barriers?
References (APA)
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Product-specific listings needed for GASTROVIST).
- FDA. Drug Approval and Databases. (For regulatory status and submission history of GASTROVIST).
